Comparative Pharmacology
Head-to-head clinical analysis: FURADANTIN versus UROBAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FURADANTIN versus UROBAK.
FURADANTIN vs UROBAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial enzymes involved in cell wall synthesis, DNA replication, and RNA transcription. It is bactericidal against susceptible organisms.
UROBAK (methenamine hippurate) is a prodrug that hydrolyzes to formaldehyde in acidic urine (pH ≤ 5.5). Formaldehyde denatures bacterial proteins and nucleic acids, exerting a broad-spectrum bacteriostatic effect. The hippurate component may enhance urinary acidification.
100 mg orally twice daily for 5-7 days; acute uncomplicated cystitis: 50 mg four times daily or 100 mg twice daily for 5 days.
500 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is 0.3-1 hour in adults with normal renal function; prolonged to 1-4 hours in renal impairment (creatinine clearance <60 mL/min) and may exceed 20 hours in anuria.
6-8 hours (prolonged in renal impairment).
Renal: 36% (glomerular filtration and tubular secretion); fecal: 40-50% (biliary excretion and unabsorbed drug); hepatic metabolism: minor (acetylation and reduction) accounting for <10%.
Primarily renal (85% unchanged); 15% biliary/fecal.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective